MARLBOROUGH, Mass.--(BUSINESS WIRE)--Aug. 21, 2002--Cetek Corporation announced today that it has entered into a screening agreement with Essential Therapeutics, Inc. The two companies entered into a previous agreement in June 2001.
Essential Therapeutics will utilize Cetek's high-throughput screening technology to discover novel antibiotics for Essential Therapeutics and its partner, Fujisawa Pharmaceutical Co., Ltd.
"We began working with Cetek a year ago and their CE Assay has proven very efficient and effective in finding early lead candidates from both synthetic and natural extract libraries" said George H. Miller, Ph.D., Executive Vice President of Essential Therapeutics.
"We are very pleased that Essential has once again demonstrated confidence in our proprietary technology by selecting us to provide screening in their new relationship involving Fujisawa, " said James N. Little, Ph.D., President of Cetek.
Cetek Corporation is a drug discovery company that is unlocking new reservoirs of natural compound diversity for the creation of novel therapeutics. Cetek integrates expertise in automation, engineering and novel strategies in natural product chemistry to utilize its capillary electrophoresis (CE) technology as a highly sensitive and robust technology for high throughput screening and compound isolation. Cetek also employs its automated CE Assay(TM) to provide contract research for pharmaceutical and biotechnology partners to advance their own synthetic and natural product drug discovery programs. Cetek has collaborations with pharmaceutical and biotechnology companies in North America, Europe and Japan.
For additional information, visit Cetek's website at cetek.com or contact Dr. James N. Little, President, at (508) 229-8900 or j.little@cetek.com. |
